Earnings call transcript: Craneware H2 2026 results disappoint as stock rises

Craneware reported fiscal 2026 revenue flat at $206 million and adjusted EBITDA of $67.1 million, or a 33% margin, while ARR remained unchanged at $185 million and adjusted EPS was stable at $1.168. Management reset fiscal 2027 revenue expectations to approximately $185 million, below reported fiscal 2026 revenue, citing a July cybersecurity incident and uncertainty in the 340B drug-pricing market. Gross margin fell 300bps to 84%, and management expects fiscal 2027 margins in the mid-to-high 20% range before targeting a return to 30%-plus margins in fiscal 2028. Shares rose 2.94% following the update, but remain roughly 58% below their 52-week high.

Analysis

The key underwriting change is not flat ARR; it is the loss of operating leverage and visibility in the variable 340B-linked layer above ARR. At approximately $185m of revenue and a mid-to-high-20% EBITDA margin, FY27 EBITDA could fall toward $48-52m versus $67m previously, before unquantified incident remediation, notification, litigation, insurance-retention and customer-security costs. A 28.6x trailing P/E therefore understates the de-rating risk: earnings power is being reset while the balance sheet is less flexible after debt-funded repurchases.

The regulatory complexity that may eventually create software demand is initially destructive for CRW because customers can defer workflow changes until rebate-model rules, litigation and state/federal standards settle. Larger hospital IT platforms and revenue-cycle vendors with broader cross-sell budgets—Oracle Health (ORCL), R1 RCM (RCM) and Veeva (VEEV) as a healthcare-software proxy—are better positioned to absorb longer sales cycles; CRW must fund security remediation and product adaptation concurrently. MSFT benefits only marginally from incremental cloud/security engagement; the partnership is not material to its earnings.

The bullish case is that the market is pricing a permanent ARR impairment despite stable retention, high cash conversion and a plausible FY28 margin recovery. That outcome requires the breach to remain contained and the new compliance product to convert regulatory friction into paid adoption; neither is independently validated yet. Over the next 1-3 months, disclosure of affected records, insurance recoveries, breach-related provisions and cost actions matter more than customer-support commentary; over 6-18 months, the decisive catalyst is whether new bookings lift net retention above 100% without further gross-margin erosion.

Key Decisions for Investors

• Avoid adding CRW into the first post-results bounce; maintain/establish a tactical short only on a recovery toward 1,150-1,250p, with a 1,450p hard stop. Base case is a retest of the 990p area over 1-3 months if FY27 EBITDA guidance/provisions imply sub-28% margin; risk/reward is roughly 2:1, but liquidity and UK small-cap borrow must be confirmed before execution.
• For existing long CRW holders, reduce exposure until the interim update quantifies cyber costs and provides a cost-base plan. Thesis is falsified positively by disclosed contained liability, no material customer claims, and FY27 exit EBITDA margin guidance of at least 28-29%; downside protection should remain in place below 990p pending those data.
• Use a relative-value expression rather than a broad healthcare-IT short: long VEEV / short CRW over 6-12 months, sized beta-neutral. VEEV offers diversified recurring growth and less binary 340B exposure, while CRW faces a potentially lower earnings base; close the spread if CRW demonstrates ARR growth above 3% and margin recovery ahead of FY28.
• Set an event alert for federal 340B rebate-pilot implementation or court injunctions. A durable delay/cancellation of restrictive manufacturer actions would be a near-term CRW cover catalyst, while implementation requiring auditable claim workflows is only bullish if CRW reports measurable OneLink bookings rather than product-launch activity.